Busulphan and Phenytoin (1989)

Letters and Corrections15 December 1989Busulphan and PhenytoinAndrew P. Grigg, MD, John D. Shepherd, MD, Gordon L. Phillips, MDAndrew P. Grigg, MDSearch for more papers by this author, John D. Shepherd, MDSearch for more papers by this author, Gordon L. Phillips, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-111-12-1049_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor:We read with interest the recent letter (1) in which antiseizure prophylaxis was recommended for patients receiving high-dose busulphan, 16 mg/kg body weight over 4 consecutive days, as part of a conditioning regimen for bone marrow transplantation. We report our experience with busulphan-induced seizures, which appear to have a characteristic clinical pattern, and their prevention with therapeutic doses of phenytoin. Since 1985, adult patients receiving high-dose busulphan at our center have been given phenytoin because of previous reports (2) of seizures thought to be busulphan-induced. Initially, a standard 300-mg dose of phenytoin (irrespective of body weight) was...References1. SuredaPérez de OteyzaGarciá LaranãOdriozola AJJJ. High-dose busulfan and seizures [Letter]. Ann Intern Med. 1989;111:543-4. LinkGoogle Scholar2. MarcusGoldman RJ. Convulsions due to high-dose busulphan [Letter]. Lancet. 1984;2:1463. CrossrefMedlineGoogle Scholar3. MartellSherJacobsMonteagudo RCPF. High-dose busulfan and myoclonic epilepsy [Letter]. Ann Intern Med. 1987;107:173. LinkGoogle Scholar4. KlawansCarveyTannerGoetz HPCC. Drug-induced myoclonus. Adv Neurol. 1986;32:251-64. Google Scholar5. HassanÖbergEhrsson MGH. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol. 1989;36:525-30. CrossrefMedlineGoogle Scholar6. HassanEhrssonSmedmyr MHB. Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplant. 1989;4:113-4. MedlineGoogle Scholar7. WinterTozer MT. Phenytoin. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Spokane, Washington: Applied Therapeutics Inc.; 1986:493-539. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Leukemia and Bone Transplantation Program of British Columbia Vancouver General Hospital Vancouver, British Columbia V5Z 4E3 Canada PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byNeurological complications in Chinese children undergoing hematopoietic stem cell transplantationNeurologic ComplicationsComparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantationPharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patientsRisk of Seizures in Children Receiving Busulphan-Containing Regimens for Stem Cell TransplantationNeurologic ComplicationsLevetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantationBusulfan in Hematopoietic Stem Cell TransplantationIPSS Poor-Risk Karyotype as a Predictor of Outcome for Patients with Myelodysplastic Syndrome following Myeloablative Stem Cell TransplantationOptimal Prevention of Seizures Induced by High-Dose BusulfanPredictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AMLNeurologic ComplicationsNeurologic complications of cancer therapyUnusual presentation of central nervous system relapse with oculomotor nerve palsy in a case of CD56-positive acute myeloid leukemia following allogeneic stem cell transplantationLorazepam for seizure prophylaxis during high-dose busulfan administrationKetobemidone May Alter Busulfan Pharmacokinetics During High-Dose TherapyThe role of busulfan in bone marrow transplantationSingle and Multi-Organ FailureCytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow TransplantationAspects Concerning Busulfan Pharmacokinetics and BioavailabilityBusulfanHigh Dose Busulphan/Cyclophosphamide for Autologous Bone Marrow Transplantation is Associated with Minimal Non-Hemopoietic ToxicityDisposition of total and unbound etoposide following high-dose therapyInfluence of prophylactic anticonvulsant therapy on high-dose busulphan kineticsBusulfan and Cyclophosphamide Versus Cyclophosphamide and Total Body Irradiation for Marrow Transplantation in Chronic Myelogenous Leukemia–A ReviewPretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: Neurological and electroencephalographic prospective studyCentral Nervous SystemSide Effects of Conditioning RegimensChronic myeloid leukaemia treated by allogeneic bone marrow transplantation from histocompatible sibling donors - an invariably fatal malignancy rendered highly curablePrevention and Management of Toxicities Associated With Antineoplastic DrugsAnticonvulsants and BusulfanWilliam E. Fitzsimmons, PharmD, MS, Richard Ghalie, MD, Herbert Kaizer, MD, PhDCorrection: Busulphan and PhenytoinAndrew P. Grigg, MDThe effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity 15 December 1989Volume 111, Issue 12Page: 1049-1050KeywordsBody weightBone marrow transplantationEpileptic seizuresProphylaxis Issue Published: 15 December 1989 PDF downloadLoading ...